Premium
ADC Therapeutics SA (ADCT)
NYSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Redmile Group, LLCSociété | -5,16M | 16,93M | Vente | 3,28 | 12,68M | -28,94% |
| 2026-03-31 | Redmile Group, LLCSociété | -716,42k | 2,70M | Vente | 3,75 - 3,80 | 12,68M | -5,35% |
| 2026-02-13 | Ms. Lisa Michelle KalleboCorporate Controller & CAO | -5,43k | 21,68k | Sale to Issuer | 3,99 | 37,39k | -12,69% |
| 2026-02-13 | Dr. Mohamed ZakiChief Medical Officer | -24,60k | 98,17k | Sale to Issuer | 3,99 | 243,88k | -9,16% |
| 2026-02-13 | Mr. Jose I. CarmonaCFO | -25,88k | 103,26k | Sale to Issuer | 3,99 | 302,78k | -7,87% |
| 2026-02-13 | Mr. Peter J. GrahamSecretary and Chief Legal & Compliance Officer | -33,29k | 132,84k | Sale to Issuer | 3,99 | 179,07k | -15,68% |
| 2026-02-13 | Dr. Ameet MallikCEO & Director | -103,23k | 411,89k | Sale to Issuer | 3,99 | 2,12M | -4,65% |
| 2025-12-06 | Dr. Ameet MallikCEO & Director | -233,15k | 767,05k | Sale to Issuer | 3,29 | 1,32M | -15,02% |
| 2025-12-06 | Mr. Peter J. GrahamSecretary and Chief Legal & Compliance Officer | -49,51k | 162,88k | Sale to Issuer | 3,29 | 139,03k | -26,26% |
| 2025-12-06 | Ms. Lisa Michelle KalleboCorporate Controller & CAO | -7,14k | 23,49k | Sale to Issuer | 3,29 | 28,86k | -19,83% |
| 2025-12-06 | Dr. Mohamed ZakiChief Medical Officer | -41,07k | 135,11k | Sale to Issuer | 3,29 | 191,82k | -17,63% |
| 2025-12-06 | Mr. Jose I. CarmonaCFO | -53,24k | 175,15k | Sale to Issuer | 3,29 | 248,66k | -17,63% |
| 2025-10-27 | Redmile Group, LLCSociété | 3,85M | 0,00 | Open Market Derivative Acquisition | - | 3,85M | - |
| 2025-06-13 | Mr. Ron SquarerChairman of the Board | -15,18k | 54,36k | Sale to Issuer | 3,58 | 53,63k | -22,07% |
| 2025-06-13 | Dr. Victor SandorIndependent Non-Executive Director | -12,60k | 45,11k | Sale to Issuer | 3,58 | 68,29k | -15,58% |
| 2025-06-13 | Ms. Viviane MongesIndependent Non-Executive Director | -2,58k | 9,25k | Sale to Issuer | 3,58 | 104,04k | -2,42% |
| 2025-06-13 | Dr. Peter HugVice-Chairman & Lead Independent Director | -2,14k | 7,68k | Sale to Issuer | 3,58 | 180,50k | -1,17% |
| 2025-06-13 | Dr. Jean-Pierre BizzariIndependent Non-Executive Director | -12,60k | 45,11k | Sale to Issuer | 3,58 | 66,90k | -15,85% |
| 2025-06-13 | Mr. Robert William AzelbyIndependent Director | -12,60k | 45,11k | Sale to Issuer | 3,58 | 40,41k | -23,77% |
| 2025-06-11 | Redmile Group, LLCSociété | 28,20M | 0,00 | Open Market Derivative Acquisition | - | 12,47M | -179,22% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
